PWM
MRNA icon

Perigon Wealth Management’s Moderna MRNA Stock Holding History

Perigon Wealth Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,570
Closed -$305K – 1017
2024
Q2 		$305K Buy
2,570
+177
+7% +$22.4K 0.01% 680
2024
Q1 		$255K Buy
+2,393
New +$241K 0.01% 726
2023
Q4 		– Sell
-2,220
Closed -$229K – 864
2023
Q3 		$229K Sell
2,220
-190
-8% -$21.2K 0.01% 690
2023
Q2 		$293K Sell
2,410
-25
-1% -$3.33K 0.01% 618
2023
Q1 		$374K Buy
2,435
+36
+2% +$5.94K 0.02% 465
2022
Q4 		$431K Sell
2,399
-2,081
-46% -$340K 0.03% 418
2022
Q3 		$530K Sell
4,480
-2,652
-37% -$402K 0.05% 321
2022
Q2 		$1.02M Buy
7,132
+479
+7% +$68.5K 0.09% 205
2022
Q1 		$1.15M Buy
6,653
+5,236
+370% +$882K 0.08% 210
2021
Q4 		$360K Buy
1,417
+58
+4% +$17K 0.03% 414
2021
Q3 		$523K Buy
1,359
+204
+18% +$75.2K 0.05% 297
2021
Q2 		$271K Buy
+1,155
New +$206K 0.02% 425
2021
Q1 		– Sell
-879
Closed -$92K – 827
2020
Q4 		$92K Buy
+879
New +$88.9K 0.01% 562

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Perigon Wealth Management's MRNA Position: Q3 2024 in Review

Perigon Wealth Management sold out of Moderna (MRNA) in Q3 2024, closing a stake of 2,570 shares — an estimated $305K sold.

Perigon Wealth Management first reported a position in MRNA in Q4 2020 and held it in 13 quarters. The position peaked at $1.15M in Q1 2022. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Perigon Wealth Management reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Perigon Wealth Management sold 2,570 Moderna shares in Q3 2024, an estimated $305K.
  • Perigon Wealth Management first reported a position in Moderna in Q4 2020 and held it in 13 quarters.
  • Perigon Wealth Management's Moderna position peaked at $1.15M in Q1 2022.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Perigon Wealth Management's 13F filing for Q3 2024, filed 16 Oct 2024.